secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001193125-24-163050
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies announces positive TSHA-102 clinical data; IDMC approves early advancement to high dose cohort
--------------------------------------------------------------------------------

- Longer-term adult data (up to 52 weeks) show durable improvements in motor, communication, autonomic, and seizure domains.
- Adult patient 1 gained ability to sit unassisted for first time in over a decade; patient 2 seizure-free for 8.5 months at 25% lower anti-seizure medication.
- Initial pediatric data (up to 22 weeks) show early developmental gains: improved hand function, gait, and communication via eye-gaze device.
- IDMC approved early advancement to high dose cohort in pediatric trial; dosing expected Q3 2024 after review of adult high dose safety.
- TSHA-102 generally well-tolerated with no drug-related serious adverse events or dose-limiting toxicities in either trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/0001193125-24-163050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/d851091d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-163050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer